|
Canada-0-WATCHES selskapets Kataloger
|
Firma Nyheter:
- Outcomes After Discontinuing BTKi Due to Adverse Effects
Patients with CLL who have to discontinue a BTK inhibitor due to adverse side effects can still experience prolonged remissions without therapy For patients with well-controlled disease, a period of close monitoring may be appropriate rather than immediately starting another therapy
- Managing toxicities of Bruton tyrosine kinase inhibitors
The long-term toxicity profile of ibrutinib, a first-in-class inhibitor, is well characterized and includes a clinically significant incidence of cardiac arrhythmias, bleeding, infection, diarrhea, arthralgias, and hypertension
- Cardiovascular Toxicities of BTK Inhibitors in Chronic . . .
Development of BTK inhibitor-associated cardiovascular events (eg, AF, VAs) are associated with worse long-term cardiovascular and overall survival
- BTK Inhibitors: present and future - PMC - PubMed Central (PMC)
Second generation kinase inhibitors may have an improved side-effect profile that may facilitate long-term use, while combination therapy approaches induce deeper remissions which opens the door to limited-duration therapy
- What are Bruton’s tyrosine kinase (BTK) inhibitors? | MD . . .
Possible BTK inhibitor side effects include fatigue, rash, diarrhea, bleeding and bruising Some patients experience neutropenia, which is caused when a patient’s white blood cell count drops That means they’re at a higher risk of infection Patients taking ibrutinib can experience an irregular heartbeat and hypertension
- Monitoring and Managing BTK Inhibitor Treatment-Related . . .
Ibrutinib treatment can be limited by adverse events (AEs) including atrial fibrillation, arthralgias, rash, diarrhea, and bleeding events, leading to drug discontinuation in 4%–26% of patients
|
|